Cited by 139RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryExtracellular vesicles in disease

Nanomedicine-Based Approaches for mRNA Delivery

Open access
Uchida, Satoshi, Perche, Federico, Pichon, Chantal, Cabral, Horacio·2020·Molecular Pharmaceutics

Abstract

Messenger RNA (mRNA) has immense potential for developing a wide range of therapies, including immunotherapy and protein replacement. As mRNA presents no risk of integration into the host genome and does not require nuclear entry for transfection, which allows protein production even in nondividing cells, mRNA-based approaches can be envisioned as safe and practical therapeutic strategies. Nevertheless, mRNA presents unfavorable characteristics, such as large size, immunogenicity, limited cellular uptake, and sensitivity to enzymatic degradation, which hinder its use as a therapeutic agent. While mRNA stability and immunogenicity have been ameliorated by direct modifications on the mRNA structure, further improvements in mRNA delivery are still needed for promoting its activity in biological settings. In this regard, nanomedicine has shown the ability for spatiotemporally controlling the function of a myriad of bioactive agents in vivo. Direct engineering of nanomedicine structures for loading, protecting, and releasing mRNA and navigating in biological environments can then be applied for promoting mRNA translation toward the development of effective treatments. Here, we review recent approaches aimed at enhancing mRNA function and its delivery through nanomedicines, with particular emphasis on their applications and eventual clinical translation.

Integrity signals

Registry

Crossref · 10.1021/acs.molpharmaceut.0c00618

Cites

297 of 297 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • mRNA has therapeutic potential in viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing.

    “mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [13]

  • mRNA normally contains five structural elements: a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions.

    “mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [13]

  • These elements can be engineered to improve the stability and translational efficiency of mRNA.

    “These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [13]

  • Many other lipid nanoparticle-mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders.

    “Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [13]

  • mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies.

    “Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [13]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Uchida, S., Perche, F., Pichon, C., & Cabral, H.
Affiliations
  • Innovation Center of NanoMedicine (JP)
  • Centre National de la Recherche Scientifique (FR)
  • Université d'Orléans (FR)
Corresponding author
Cabral, Horacio
Venue
Molecular Pharmaceutics
Published
2020-08-26
Volume
17
Issue
10
Pages
3654-3684
ISSN
  • 1543-8384 (ISSN-L)
  • 1543-8392
OpenAlex
W3080316114
Cited by
139
References
297
Citations by year
2026: 10 · 2025: 17 · 2024: 26 · 2023: 30 · 2022: 27 · 2021: 24 · 2020: 4
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • Molecular Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
Japan Society for the Promotion of Science (18K19901, 20H04524, JP16H03179)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
mRNA delivery, nanomedicine, mRNA therapeutics, mRNA stability, mRNA modification, cellular uptake, controlled release, in vivo targeting, clinical translation, immunotherapy, protein replacement therapy
MeSH terms
Animals, Chemical Engineering, Chemistry, Pharmaceutical, Drug Carriers, Drug Stability, Humans, Immunotherapy, RNA, Messenger, Nanomedicine, Nanoparticles, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review